(Q57579999)

English

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

scientific article published on 01 July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

cancer research

0 references

0 references

estrogen-receptor positive breast cancer

0 references

phase II clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Garik A Dashyan

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Alexander Kletzel

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Vladimir F Semiglazov

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Vladislav V Semiglazov

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Elena K Ziltsova

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Vadim G Ivanov

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Alla A Bozhok

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Olga A Melnikova

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ruslan M Paltuev

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lev M Berstein

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

0 references

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

110

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

244-254

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative (neoadjuvant) systemic treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22789

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22789

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17538978%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57579999&oldid=1997945010"